OGN News and Press, Organon & Co. From 08/01/23

INCHEON, South Korea and JERSEY CITY, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced topline results from the interchangeability study for SB5, a biosimilar to Humira ® (adalimumab). The Phase 4, randomized, double-blin...

2023-07-28 13:25:00 ET Summary Sound Shore Fund, Inc. is registered as a diversified, open-end management investment company. The investment objective of the Fund is growth of capital. The Sound Shore Fund Investor Class and Institutional Class outperformed the Russell 1000 Value ...

2023-07-26 16:27:28 ET Summary The Fed raised rates by 25 bps, as widely expected. Impact on high-yield S&P 500 stocks discussed. S&P 500 at 4,700 assessed. Expectations of 2% inflation in 2025 at the earliest discussed. The Federal Reserve raised interest ra...

2023-07-26 03:15:00 ET Summary Miller Value Partners is a value investor. It values businesses, and not just stocks, and invests in them for the long term. Miller Income Strategy's representative account generated a 3.14% net return in Q2 2023, outperforming the ICE BofA US High Y...

2023-07-21 08:30:00 ET In retirement, seniors on average see an annual shortfall of about $4,000 between the income they generate and the expenses they incur, according to data from the Bureau of Labor Statistics.. Whether you want to protect yourself from unexpected healthcare expense...

2023-07-17 08:05:00 ET Summary Organon, a global healthcare company, is a buy for value and income investors due to its strong growth in biosimilars business and 5.5% dividend yield. Despite a 20% YoY decline in adjusted EBITDA, the company has seen constant currency product sales...

VANCOUVER, BC / ACCESSWIRE / July 17, 2023 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to provide an update and forecast on its partner-funded project generation portfolio for 2023. Highlights Estimated 28,000 metres of partner funded drilling fo...

Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2023 financial results on August 8, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast on the Organ...

2023-07-16 01:17:15 ET Summary Organon & Co's share price has fallen significantly, with a p/e below the sector average and a 5.4% dividend yield, but its cash flows are barely above its nearly $300 million dividend, potentially limiting dividend growth. The company recently m...

2023-07-05 12:57:34 ET South Korea's Celltrion ( OTC:CONIF ) has launched a high-concentration, citrate-free formulated biosimilar of AbbVie's ( NYSE: ABBV ) Humira in the US. The biosimilar, which is called Yuflyma, was approved by the FDA in May. Yuflyma's list price is $6...